

## PRIOR AUTHORIZATION POLICY

**POLICY:** Botulinum Toxin – Dysport Prior Authorization Policy

- Dysport® (abobotulinumtoxinA injection – Ipsen)

**REVIEW DATE:** 01/11/2023

---

### OVERVIEW

Dysport (abobotulinumtoxinA), is indicated for the following uses:<sup>1</sup>

- **Cervical Dystonia** in adults.
- **Spasticity** in patients  $\geq 2$  years of age.

Toxin distribution varies between the commercially available botulinum toxin A products, Botox® (onabotulinumtoxinA), Xeomin® (incobotulinumtoxinA), and Dysport.<sup>1-4</sup> It has been postulated that differences in albumin concentration control diffusion of toxin from the injection site (Botox contains 500 mcg of albumin, while Dysport contains 125 mcg of albumin and Xeomin contains 1 mg of albumin). In addition, the labels for the botulinum toxin type A products (Botox, Dysport, and Xeomin) state that there is a lack of interchangeability between the products for various reasons, including differences in the units of biological activity.<sup>1,2,4</sup> Studies have attempted to establish a conversion ratio between botulinum toxin products, with variable results. In general, conversion ratios of 1:1 for Botox to Xeomin, 1:3 for Botox to Dysport, and 1:50 to 1:100 for Botox to Myobloc have been suggested.<sup>5,6</sup>

### Other Uses with Supportive Evidence

Botulinum toxins, including Dysport, have been studied in a variety of indications outside of FDA-approved uses. Literature is available to support use of Dysport in the following conditions:

- **Anal Fissure:** There is an extensive amount of data from open-label studies; randomized, placebo-controlled trials; and randomized, comparative trials supporting the efficacy of botulinum toxin A in the treatment of anal fissures.<sup>7-9</sup> Injection of botulinum toxin allows healing in approximately 60% to 80% of anal fissures.<sup>10</sup> There is no consensus on the dose, site of injection, or number of injections. Botulinum toxin A has been shown to be more effective than topical nitroglycerin but less effective than surgery in inducing and maintaining fissure healing.<sup>11</sup> The American College of Gastroenterology clinical guideline for the management of benign anorectal disorders (2021) suggests that botulinum toxin A injections may be attempted for patients in whom calcium channel blockers fail or as an alternative option to calcium channel blockers (conditional recommendation; quality of evidence low).<sup>9</sup>
- **Blepharospasm:** Dysport has demonstrated efficacy in clinical trials in patients with blepharospasm.<sup>12,13</sup> American Academy of Neurology (AAN) guidelines (2016, reaffirmed 2022) support the use of Dysport for blepharospasm with a Level C recommendation (“possibly effective”).<sup>14</sup>
- **Hemifacial Spasm:** Per the AAN, botulinum toxin (formulation not specified) may be considered in hemifacial spasm (Level C).<sup>19</sup> Data with Botox and Dysport are cited in the recommendations regarding hemifacial spasm.
- **Sialorrhea, Chronic:** Botulinum toxin A has been studied in the treatment of sialorrhea associated with Parkinson’s Disease, parkinsonian syndromes, cerebral palsy, head and neck carcinoma, neurodegenerative disease, stroke, and amyotrophic lateral sclerosis.<sup>16-18</sup> Data with Dysport come from two small controlled trials.<sup>16,17</sup> AAN guidelines state that botulinum toxin is probably safe and effective and should be considered (Level B).<sup>15</sup>

### POLICY STATEMENT

01/11/2023

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Prior Authorization is recommended for prescription benefit coverage of Dysport. All approvals are provided for 1 year.

Prior Authorization and prescription benefit coverage are not recommended for cosmetic conditions.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Dysport is recommended in those who meet one of the following criteria:

#### **FDA-Approved Indications**

1. **Cervical Dystonia.** Approve for 1 year.  
Note: Cervical dystonia is also known as spasmodic or cervical torticollis.
2. **Spasticity, Limb.** Approve for 1 year.

#### **Other Uses with Supportive Evidence**

3. **Anal Fissure.** Approve for 1 year.
4. **Blepharospasm.** Approve for 1 year.
5. **Hemifacial Spasm.** Approve for 1 year.
6. **Sialorrhea, Chronic.** Approve for 1 year.

### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Dysport is not recommended in the following situations:

1. **Cosmetic Uses.** Note: Examples of cosmetic uses include facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid and lower face and neck rejuvenation, platysmal bands, or rejuvenation of the periorbital region. Cosmetic use is not recommended for coverage as this indication is excluded from coverage in a typical pharmacy benefit.
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### **REFERENCES**

1. Dysport® injection [prescribing information]. Cambridge, MA and Fort Worth, TX: Ipsen/Galderma; July 2020.
2. Botox® injection [prescribing information]. Madison, NJ: Allergan; August 2022.
3. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. *J Urol.* 2004;17(6 Pt 1):2128-2137.
4. Xeomin® injection [prescribing information]. Raleigh, NC: Merz; August 2021.
5. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. *J Clin Aesthet Dermatol.* 2014;7(2):31-39.
6. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. *Toxins (Basel).* 2016;8(3):65.
7. Brisinda G, Bentivoglio AR, Maria G, et al. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. *Mov Disord.* 2004;19(Suppl 8):S146-S156.

8. Friedenberf F, Gollamudi S, Parkman HP. The use of botulinum toxin for the treatment of gastrointestinal motility disorders. *Dig Dis Sci*. 2004;49(2):165-175.
9. Wald A, Bharucha AE, Limketkai B, et al. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2021 Oct 1;116(10):1987-2008.
10. Bansal C, Omlin KJ, Hayes CM, et al. Novel cutaneous uses for botulinum toxin type A. *J Cosmet Dermatol*. 2006;5(3):268-272.
11. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: A review, part 2. *Am J Health Syst Pharm*. 2006;63(3):225-232.
12. Truong D, Comella C, Fernandez HH, et al.; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. *Parkinsonism Relat Disord*. 2008;14(5):407-14.
13. Kollwe K, Mohammadi B, Köhler S, et al. Blepharospasm: long-term treatment with either Botox<sup>®</sup>, Xeomin<sup>®</sup> or Dysport<sup>®</sup>. *J Neural Transm*. 2015;122(3):427-31.
14. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86:1818-1826.
15. Naumann M, So Y, Argoff AE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008;70:1707-1714.
16. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. *J Neurol Sci*. 2005;235(1-2):1-9.
17. Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations. *Eur J Neurol*. 2006;13 (Suppl 1):60-64.
18. Sheffield JK, Jakovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. *Expert Rev Neurotherapeutics*. 2007;7(6):637-647.
19. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008;70:1699-1706.